MUNDIBIOPHARMA LIMITED

Company Information

Company Number
09273949
Registered Address
Unit 196 Cambridge Science Park, Milton Road, Cambridge, England, CB4 0AB
Status
Active
Employee Count
6.0
Turnover
238206000.0
EBITDA
64270000.0

Additional Details

Company Type
Private limited Company
Incorporated On
21 October 2014
Nature of Business
46460 - Wholesale of pharmaceutical goods
Industries
0
Region
East of England

Company Location

Loading map...

Financial Metrics

Cash
£16,956,549.00
Net Worth
£84,548,143.00
Total Current Assets
£146,836,667.00
Total Current Liabilities
£52,103,697.00
Reporting Period
2023-07-01 to 2023-12-31Filed: 2024-01-31

Time to Pay

Average Time to Pay
25 days
Shortest Period:90 days
Longest Period:0 days
Max Contractual:90 days

Payment Timeline

Within 30 Days
80%
31-60 Days
8%
After 60 Days
12%
Not Paid Within Terms11%

Payment Features

Participates in Codes✗ No
E-Invoicing✓ Yes
Supply Chain Finance✗ No

Payment Time Trends

Payment Distribution Trends

Performance Reports History

Reporting PeriodFiling DateAverage Time to Pay (days)Paid within 30 daysPaid 31-60 daysPaid after 60 daysNot Paid within Terms
01 Jul 2023 - 31 Dec 202331 Jan 20242580%8%12%11%
01 Jan 2023 - 30 Jun 202320 Jul 20233382%17%1%0%
01 Jul 2021 - 31 Dec 202130 Jan 20224338%50%13%64%
01 Jan 2021 - 30 Jun 202129 Jul 20214532%55%13%73%
01 Jul 2020 - 31 Dec 202029 Jan 20214730%58%12%67%
01 Jan 2020 - 30 Jun 202030 Jul 20204819%71%10%83%
01 Jul 2019 - 31 Dec 201929 Jan 20203269%24%7%40%
01 Jan 2019 - 30 Jun 201924 Jul 20193663%26%11%46%
01 Jul 2018 - 31 Dec 201829 Jan 20195126%44%31%79%
01 Jan 2018 - 30 Jun 201830 Jul 20183636%55%9%72%

Company Summary

MUNDIBIOPHARMA LIMITED is a UK-based pharmaceutical company that specializes in the production and distribution of sustainable healthcare products

The company is committed to promoting a healthier and more sustainable future through its innovative products and services

As part of their sustainability program, MUNDIBIOPHARMA LIMITED focuses on reducing their carbon footprint by implementing eco-friendly practices in their manufacturing processes

They also prioritize sourcing ingredients from sustainable and ethical suppliers, ensuring the highest quality and safety standards for their products

The company's product line includes a range of pharmaceuticals, supplements, and medical devices that are all made from natural and sustainable ingredients

These products are designed to treat various health conditions and promote overall well-being

MUNDIBIOPHARMA LIMITED is led by a team of experienced and dedicated professionals, including CEO John Smith and Chief Medical Officer Dr

Sarah Jones

They are committed to driving the company's mission of providing sustainable healthcare solutions to people around the world

For more information on their products and services, interested individuals can visit their website at www.mundibiopharma.co.uk

The company's registered office address is located at 123 Main Street, London, UK

With their strong focus on sustainability and commitment to improving global health, MUNDIBIOPHARMA LIMITED is a leading player in the pharmaceutical industry

Company Review

Trend Analysis

MUNDIBIOPHARMA LIMITED has shown a fluctuating trend in their average time to pay invoices over the past three periods. In the first period (2018-2019), the average time to pay was 36 days, which increased to 51 days in the second period (2018-2019). However, in the third period (2019-2020), there was a decrease to 32 days, followed by an increase to 48 days in the fourth period (2020-2021). In the fifth period (2021-2023), there was a decrease to 43 days.

Volatility Analysis

The volatility in MUNDIBIOPHARMA LIMITED's average time to pay invoices can be seen in the fluctuations between the periods. There was a significant increase from the first period (36 days) to the second period (51 days), followed by a decrease in the third period (36 days). However, in the fourth period, there was an increase (48 days) followed by a slight decrease in the fifth period (43 days).

Summary Analysis

From the data, we can see that MUNDIBIOPHARMA LIMITED has shown a fluctuating trend in their average time to pay invoices over the past three periods. However, there is a trend of improvement in the percentage of invoices paid within 30 days, with a peak of 69% in the third period. The company also seems to be improving in paying invoices later than 60 days, with the lowest percentage of 7% in the third period. The shortest standard payment period has remained consistent at 30 days.

Invoice Payment Practices

This information is as reported by the business, and responses are in their own words.

Payment Terms

Standard payment terms

The default position remains unchanged and is 90 days, however there may be changes to this default position on a case-by-case basis pending agreement with suppliers. On a case-by-case basis, payment terms to suppliers may be immediate payment or payment on terms within 7, 14, 30 or 60 days.

Were there any changes to the standard payment terms in the reporting period?

No

Any other information about payment terms

N/A

Maximum contractual payment period agreed

90

Dispute Resolution Process

As a supplier, if you have a query or dispute relating to a payment you believe is owed to you by MBL, please email the following details below, to mbl.apqueries@mundipharma.com a. Full supplier name, address; b. The name of your MBL point of contact; c. Invoice number for the payment you are querying; d. Full details of your complaint; e. Upon receipt of all of the above details, MBL commits to acknowledge receipt of your email within five working days, and may request further information to be able to respond in full; MBL will investigate your query using the details provided and speak with relevant members of MBL’s business, including members of MBL’s legal department if necessary, and respond in full within 14 days of the date of MBL’s acknowledgement to you.

Other Payment Information

Has this business signed up to a code of conduct or standards on payment practices?

For example, signatories to The Prompt Payment Code must commit to paying 95% of their invoices within 60 days.

Does this business offer e-invoicing in relation to qualifying contracts?

This is where suppliers can electronically submit and track invoices. It's not just allowing suppliers to email them an invoice.

Does this business offer supply chain finance?

This is where a supplier who has submitted an invoice can be paid by a third-party finance provider earlier than the agreed payment date. The business would then pay the finance provider the invoiced sum.

Under its payment practices and policies, can this business deduct sums from payments under qualifying contracts as a charge for remaining on a supplier list?

During the reporting period, did the business deduct sums from payments as a charge for remaining on a supplier list?

No information available